Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in May 2016 on request of the Sponsor.

On 2 April 2008, orphan designation (EU/3/08/538) was granted by the European Commission to Pharmion Ltd, United Kingdom, for amrubicin hydrochloride for the treatment of small-cell lung cancer.

The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in December 2008.

Key facts

Active substance
Amrubicin hydrochloride
Disease / condition
Treatment of small cell lung cancer
Date of first decision
EU designation number

Sponsor's contact details

Celgene Europe Limited
1 Longwalk Road
Stockley Park
Middlesex UB11 1DB
United Kingdom
Telephone: +44 208 831 83 00
Telefax: +44 208 831 83 01

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating